Insider at

04

Insider transactions

05
0 buys (P) 1 sells (S) Net: $-258,894 + 8 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

8 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Aug. 19, 2026 BHC S 10b5-1 36,827 $7.03 $258,894 334,853 Direct -9.91% Disposed -17.5% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

BHC

President, US Pharma
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2025 $650,000 · $1,958,861 · $628,880 · $26,750 $3,264,491

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.